News - AbbVie

Filter

Current filters:

AbbVie

Popular Filters

1 to 25 of 64 results

EMA confirms AbbVie’s withdrawal of court cases on access to clinical-trial data

04-04-2014

The European Medicines Agency confirms that US drugmaker AbbVie has withdrawn both its court cases brought…

AbbVieEuropeLegalPharmaceuticalResearch

Lupin launches generic Niaspan in USA

24-03-2014

Indian drugmaker Lupin says that its US subsidiary has launched its niacin extended-release tablets USP,…

AbbVieCardio-vascularGenericsLupinMarkets & MarketingNiaspanNorth AmericaUSA

Global microvascular complications of diabetes market value to almost double by 2022

Global microvascular complications of diabetes market value to almost double by 2022

20-03-2014

The microvascular complications of diabetes pharmaceutical market value in the seven major countries…

AbbVieatrasentanDiabetesGlobalMarkets & MarketingPharmaceutical

AbbVie presents positive Phase III results in patients with chronic hepatitis C

AbbVie presents positive Phase III results in patients with chronic hepatitis C

04-03-2014

The first detailed results from US drugmaker AbbVie’s pivotal Phase III study, PEARL-III, have been…

AbbVieAntibiotics and Infectious diseasesPharmaceuticalResearchUSA

Viiv Healthcare comes out top in global survey of pharma industry reputations

14-02-2014

An independent global study has recorded the latest impressions of the corporate reputation of the world’s…

AbbVieGlobalPharmaceuticalResearchViiV Healthcare

AbbVie to spend $320 million to establish Singapore manufacturing presence

AbbVie to spend $320 million to establish Singapore manufacturing presence

06-02-2014

US drugmaker AbbVie says it plans to invest $320 million to establish operations in Singapore for small…

AbbVieAsia-PacificImmunologicalsOncologyPharmaceuticalProduction

AbbVie’s hepatitis C Phase III trials all record top results

AbbVie’s hepatitis C Phase III trials all record top results

04-02-2014

US drugmaker AbbVie has announced the completion of its Phase III clinical program and released results…

AbbVieAntibiotics and Infectious diseasesPharmaceuticalResearchUSA

AbbVie sees profits downturn but meets analysts’ expectations

AbbVie sees profits downturn but meets analysts’ expectations

01-02-2014

US drugmaker AbbVie’s shares gained 3% to $49.77 in morning trading on January 31, when the company…

AbbVieFinancialPharmaceutical

Seattle Genetics expands cancer drug collaboration with AbbVie

Seattle Genetics expands cancer drug collaboration with AbbVie

09-01-2014

US biotech firm Seattle Genetics says it has further expanded its antibody-drug conjugate (ADC) collaboration…

AbbVieBiotechnologyLicensingOncologySeattle Genetics

Sandoz launches Phase III trial of biosimilars of AbbVie’s Humira

Sandoz launches Phase III trial of biosimilars of AbbVie’s Humira

19-12-2013

Sandoz, the generics unit of Swiss drug major Novartis (NOVN: VX), has initiated a Phase III clinical…

AbbVieBiosimilarsHumiraImmunologicalsNorthern EuropeResearchSandoz

Positive results Ph II results for AbbVie’s veliparib in breast cancer

Positive results Ph II results for AbbVie’s veliparib in breast cancer

14-12-2013

The I-SPY 2 trial, an innovative, multidrug, Phase II breast cancer study, has yielded positive results…

AbbVieOncologyPharmaceuticalResearchveliparib

AbbVie reports 96% response in Phase III hepatitis C study

AbbVie reports 96% response in Phase III hepatitis C study

10-12-2013

US drugmaker AbbVie (NYSE: ABBV)has released Phase III results for the investigational three direct-acting-antiviral…

AbbVieAnti-viralsAntibiotics and Infectious diseasesPharmaceuticalResearchUSA

Health Canada clears AbbVie’s Humira for UC

Health Canada clears AbbVie’s Humira for UC

28-11-2013

In what is now the eighth indication in Canada for its top-selling drug Humira (adalimumab), US drugmaker…

AbbVieAnti-Arthritics/RheumaticsGastro-intestinalsHumiraNorth AmericaPharmaceuticalRegulation

AHF sues Abbott and AbbVie for overcharging on AIDS drug pricing

AHF sues Abbott and AbbVie for overcharging on AIDS drug pricing

28-11-2013

In further legal action against drugmakers allegedly over pricing AIDS drugs in the USA, the AIDS Healthcare…

Abbott LaboratoriesAbbVieAnti-viralsKaletra TabletsLegalNorth AmericaNorvirPharmaceuticalPricing

AbbVie releases positive Phase III results for oral hepatitis C program

AbbVie releases positive Phase III results for oral hepatitis C program

18-11-2013

US drugmaker AbbVie has released the first Phase III results for the investigational three direct-acting-antiviral…

AbbVieAntibiotics and Infectious diseasesNorth AmericaPharmaceuticalResearchUSA

New ACC and AHA guidelines could increase sales of statins

New ACC and AHA guidelines could increase sales of statins

13-11-2013

New clinical guidelines have been published for the treatment of cholesterol in people at high risk of…

AbbVieAstraZenecaCardio-vascularCrestorHealthcareLipitorMerck & CoNorth AmericaPfizerPharmaceuticalTricorUSAZetia

Morningstar analysts find GlaxoSmithKline has strongest pipeline

Morningstar analysts find GlaxoSmithKline has strongest pipeline

06-11-2013

Morningstar, an independent Chicago-based investment research firm, recently published the November 2013…

AbbVieAstraZenecaBayerFinancialGlaxoSmithKlineMerck & CoPharmaceuticalResearchSanofi

European prescribing attitudes for rheumatoid arthritis post-ADACTA

European prescribing attitudes for rheumatoid arthritis post-ADACTA

28-10-2013

Results from the ADACTA trial, which showed that Swiss drug major Roche’s RoActemra (tocilizumab) is…

AbbVieAnti-Arthritics/RheumaticsBiotechnologyEuropeHumiraMarkets & MarketingPfizerRoActemraRochetofactinib

Accelerated growth for AbbVie’s Humira lifts 3rd-quarter results above expectation

Accelerated growth for AbbVie’s Humira lifts 3rd-quarter results above expectation

27-10-2013

Shares of AbbVie were up 2.4% at $49.09 in afternoon trading on the New York Stock Exchange on Friday,…

AbbVieFinancialHumiraPharmaceutical

1 to 25 of 64 results

Back to top